PROCTER & GAMBLE HEALTH | VILIN BIO MED | PROCTER & GAMBLE HEALTH/ VILIN BIO MED |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | - | - | View Chart |
P/BV | x | 10.6 | 2.7 | 384.7% | View Chart |
Dividend Yield | % | 2.0 | 0.0 | - |
PROCTER & GAMBLE HEALTH VILIN BIO MED |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
VILIN BIO MED Mar-23 |
PROCTER & GAMBLE HEALTH/ VILIN BIO MED |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | NA | - | |
Low | Rs | 3,883 | NA | - | |
Sales per share (Unadj.) | Rs | 740.7 | 12.4 | 5,985.8% | |
Earnings per share (Unadj.) | Rs | 138.2 | 1.3 | 11,047.7% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 1.4 | 10,926.2% | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | 10.7 | 4,171.0% | |
Shares outstanding (eoy) | m | 16.60 | 9.95 | 166.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 0 | - | |
Avg P/E ratio | x | 33.5 | 0 | - | |
P/CF ratio (eoy) | x | 29.8 | 0 | - | |
Price / Book Value ratio | x | 10.3 | 0 | - | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 0 | - | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 8 | 26,534.1% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 123 | 9,986.4% | |
Other income | Rs m | 184 | 0 | 76,625.0% | |
Total revenues | Rs m | 12,480 | 123 | 10,116.0% | |
Gross profit | Rs m | 3,247 | 26 | 12,618.7% | |
Depreciation | Rs m | 281 | 2 | 16,726.2% | |
Interest | Rs m | 8 | 6 | 118.8% | |
Profit before tax | Rs m | 3,142 | 18 | 17,631.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 5 | 15,778.4% | |
Profit after tax | Rs m | 2,295 | 12 | 18,431.3% | |
Gross profit margin | % | 26.4 | 20.9 | 126.3% | |
Effective tax rate | % | 27.0 | 30.1 | 89.5% | |
Net profit margin | % | 18.7 | 10.1 | 184.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 133 | 8,817.2% | |
Current liabilities | Rs m | 6,791 | 65 | 10,439.4% | |
Net working cap to sales | % | 40.0 | 55.1 | 72.7% | |
Current ratio | x | 1.7 | 2.0 | 84.5% | |
Inventory Days | Days | 263 | 86 | 306.9% | |
Debtors Days | Days | 343 | 2,927 | 11.7% | |
Net fixed assets | Rs m | 10,617 | 44 | 24,129.3% | |
Share capital | Rs m | 166 | 100 | 166.8% | |
"Free" reserves | Rs m | 7,265 | 7 | 99,787.1% | |
Net worth | Rs m | 7,431 | 107 | 6,958.7% | |
Long term debt | Rs m | 0 | 4 | 0.0% | |
Total assets | Rs m | 22,330 | 177 | 12,627.8% | |
Interest coverage | x | 409.1 | 3.8 | 10,908.1% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.7 | 79.1% | |
Return on assets | % | 10.3 | 10.7 | 96.3% | |
Return on equity | % | 30.9 | 11.7 | 264.9% | |
Return on capital | % | 42.4 | 21.9 | 193.8% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | NA | - | |
Fx inflow | Rs m | 1,465 | 0 | - | |
Fx outflow | Rs m | 1,605 | 0 | - | |
Net fx | Rs m | -140 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | -17 | -14,234.0% | |
From Investments | Rs m | -215 | NA | 71,666.7% | |
From Financial Activity | Rs m | -985 | 17 | -5,847.4% | |
Net Cashflow | Rs m | 1,160 | 0 | -2,900,750.0% |
Indian Promoters | % | 0.0 | 64.5 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 0.0 | - | |
FIIs | % | 6.2 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 35.5 | 135.8% | |
Shareholders | 56,778 | 585 | 9,705.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | VILIN BIO MED | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 5.00% | 0.45% |
1-Month | -1.15% | 8.81% | 2.55% |
1-Year | 0.73% | -10.64% | 56.14% |
3-Year CAGR | -8.76% | -3.68% | 15.22% |
5-Year CAGR | 4.97% | -2.22% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the VILIN BIO MED share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of VILIN BIO MED the stake stands at 64.5%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of VILIN BIO MED.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
VILIN BIO MED paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of VILIN BIO MED.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.